6 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG) Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a...
General Releases
ADR Ratio Change
22 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain,...
Results of Annual General Meeting and General Meeting
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting and General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of products aimed...
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering
26 May 2023 Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of products...
Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT...
Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
18 May 2023 Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline...
Preliminary Results for the Year Ended 31 December 2022
28 April 2023 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2022 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company...
Closing of $6.0m Private Placement & Broker Change
Midatech Pharma PLC ("Midatech" or the "Company") Closing of US$6.0 million Private Placement Change of Broker Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines,...
Private Placement Raising US$6.0 million
Midatech Pharma PLC ("Midatech" or the "Company") Private Placement Raising US$6.0 million Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces that it has...
Planned Dose Escalation in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that following completion of one month of treatment with MTX-110 in the first patient, its...
First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the enrolment of the first patient into its Phase 1 study of MTX110 in recurrent...
Orphan Designation Granted by EMA to MTX110 Development for the Treatment of Glioma
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that following the submission of an application to the European Medicines Agency (“EMA”),...
An Update to MTX110 Study in Pediatric Patients with DIPG
An Update to MTX110 Study in Pediatric Patients with DIPG to be Presented at The International Symposium on Pediatric Neuro-Oncology, Hamburg, Germany (ISPNO 2022) Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving...
Fast Track Designation Granted to MTX110 Development for the Treatment of Recurrent Glioblastoma
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that upon submitting an application to the U.S. Food and Drug Administration ("FDA"), its...
IND Application for MTX110 Study in GBM Effective
Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is...
Midatech Pharma welcomes Dr Dmitry Zamoryakhin as Chief Scientific Officer
Dmitry is a medically trained professionalmedical doctor with over 17 years of experience in drug and medical devices development. “It is a great pleasure and privilege to join the fantastic team at Midatech Pharma. The company’s ‘multiple shots on goal’ strategy...
Targeting Technology offers hope for cancer patients
This article was written by Raconteur for The Times’ Combatting Cancer publication on 30th June 2021Read the report - External link Cancer treatment has come a long way, but there are still challenges in delivering life-saving drugs to patients without compromising...
Breakthrough data using Q-Sphera technology
Breakthrough data on the successful encapsulation of a biologic using Q-Sphera technology Significant progress across multiple other R&D programmes Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the...
MTX110 Programmes to be presented at ISPNO 2020
MTX110 Programmes to be Presented at The International Symposium on Pediatric Neuro‐Oncology, Karuizawa, Japan (ISPNO 2020) Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio‐delivery and biodistribution of...
UK Parliament Highlights Need for New DIPG Treatments
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the biodelivery and biodistribution of medicines, is pleased to note that its research effort to find novel treatments for Diffuse Intrinsic Pontine Glioma ("DIPG")...
MTX110 presented at 2020 Annual SNO Conference
MTX110 Phase I Trial Results in DIPG and Preclinical Efficacy Data in Glioblastoma presented at 2020 Annual SNO Conference Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of...
UK Placing to Raise £5.0 million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE...
Collaboration for the Q-Sphera platform
Midatech adds to collaborative business model for the Q-Sphera platform Midatech Pharma's next generation drug delivery technologies to be applied to new modalities in collaboration with a European pharmaceutical company. Cardiff, UK, 21 July 2020: Midatech Pharma PLC...
Research collaboration with Dr Reddy’s
Midatech enters into research collaboration with Dr Reddy's Laboratories Ltd (Dr Reddy's") Midatech Pharma's next generation drug delivery technologies for comprehensively improving bio-delivery and bio-distribution to be applied to existing medicines in collaboration...